Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups

Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors

Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease 

Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time 

In the NICHE-3 study, all patients achieved a pathological response  

Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens 

Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting 

Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed 

In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types

Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease